Cross-Sector entity
The 160-day window averages about 0.3 stories each week. The busiest single day carried 3. Of the tracked stories, 3 of 7 also mention Eli Lilly, the most common co-covered peer. markets accounts for 2 of the 7 tracked stories, while 4 other categories carry the remainder.
7 verified stories tracked
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 14 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The 160-day window averages about 0.3 stories each week. The busiest single day carried 3. Of the tracked stories, 3 of 7 also mention Eli Lilly, the most common co-covered peer. markets accounts for 2 of the 7 tracked stories, while 4 other categories carry the remainder. Negative sentiment appears in 0% of the tracked stories. We currently track 7 Cross-Sector stories that mention RBC Capital, published between February 27, 2026 and August 5, 2026. Each carries 2 original sources on average.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RBC Capital. Shared-story counts are live from our verified record — not editorial picks.
SEC filings and market close
Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
Insider sales executed
Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
Q1 2026 earnings
uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
RBC upgrade
RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Source: dailypolitical.com · themarketsdaily.com
Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector.
Source: benzinga.com
RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market.
RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector.
RBC Capital reaffirms Eli Lilly’s Retatrutide as a critical future growth engine, despite recent mixed clinical trial data. The triple-agonist therapy is expected to redefine the weight-loss market by offering superior efficacy compared to existing dual-agonist treatments.
Source: insidermonkey.com · finance.yahoo.com
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Source: finance.yahoo.com · insidermonkey.com
